A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old

NCT00927498 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

280

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: conventional chemotherapy (AraC + Daunorubicin),
DRUG: Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),

Sponsor

Acute Leukemia French Association

Collaborators

[object Object]